Issue 74, 2022

A nanoplatform for mild-temperature photothermal and type I & II photodynamic therapy in the NIR-II biowindow

Abstract

In the current work, we synthesized an A–D–A smallmolecule photosensitizer, denoted as DPTTIC, and a dual PEG-functionalized pillararene, denoted as WP5-8C-2PEG, and used them to construct novel DPTTIC nanoparticles (NPs) displaying NIR II absorption. Under 980 nm-wavelength laser irradiation, DPTTIC NPs performed well in mild-temperature photothermal and type I & II photodynamic anti-tumor therapy.

Graphical abstract: A nanoplatform for mild-temperature photothermal and type I & II photodynamic therapy in the NIR-II biowindow

Supplementary files

Article information

Article type
Communication
Submitted
09 Jun 2022
Accepted
18 Aug 2022
First published
18 Aug 2022

Chem. Commun., 2022,58, 10353-10356

A nanoplatform for mild-temperature photothermal and type I & II photodynamic therapy in the NIR-II biowindow

B. Lu, Z. Zhang, Y. Huang, Y. Zhang, J. Wang, Y. Ding, Y. Wang and Y. Yao, Chem. Commun., 2022, 58, 10353 DOI: 10.1039/D2CC03248A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements